Proven efficacy & safety on real patients

There are many challenges that come with treating osteoarthritis (OA) in dogs, from concerns about early diagnosis and long-term safety, to targeting both the pain and inflammation of this chronic condition. Galliprant™ is an NSAID you can trust for the safe and effective treatment of OA in your canine patients, no matter what stage of their OA journey they are at. Galliprant has been firmly established as an excellent first-line option in the OA treatment space, already improving the quality of life for hundreds of thousands of dogs across the world. After all, an NSAID with an impressive safety profile¹ means less stress for all.

A targeted approach to alleviating both pain & inflammation

Specifically designed for canine OA, Galliprant selectively blocks only the EP4 receptor to effectively control both pain and inflammation associated with OA in dogs. It is the ONLY NSAID to offer this targeted approach, so unlike COX-inhibiting NSAIDs, Galliprant conserves the production of important house-keeping prostaglandins involved in GIT and renal homeostasis². The benefits of this targeted mode of action are highlighted by the results of a target animal safety study¹. In this study, Galliprant was administered up to 10 times the maximum therapeutic dose daily for nine months. Even at these high daily doses for an extended period of time, Galliprant was well-tolerated – all dogs completed the study in a clinically normal fashion, with no evidence of GI ulceration, and no kidney or liver problems.

Your trusted choice for OA relief in dogs

The unfortunate reality of OA is that there is no cure, which means long-term treatment is the best course of action to make patients more comfortable. Some dog owners and vets are reluctant to prescribe NSAIDs long-term, especially for young patients, for fear of inducing damaging side-effects on their patients³, but Galliprant can be administered safely for life if necessary.

If you’ve been searching for a safe and effective NSAID to treat both early and long-term OA cases, Galliprant is the name you can trust. It’s a tried-and-true treatment backed by vets, science and research studies, so you can prescribe it with peace of mind.

“While osteoarthritis is often associated with old age, this is often not the case in dogs. Canine OA affects many young dogs and these dogs benefit greatly from adequate analgesia that is administered appropriately. Galliprant™ is very effective at treating the pain and inflammation associated with canine osteoarthritis, and it has become my NSAID of choice for the long-term treatment of canine OA. It is important to note that a multimodal approach is required to achieve the best outcome. Using Galliprant together with nutraceuticals and a tailored dietary and exercise regimen is key in achieving a successful outcome.”

Dr. Simon T. Kudnig BVSc, MVS, MS, FACVSc, Dip.ACVS

Specialist in Small Animal Surgery

ACVS Founding Fellow of Surgical Oncology

^{Read product leaflet for full instructions. The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetance and lethargy. For long-term treatment, appropriate monitoring is recommended. The safety of Galliprant has not been established in dogs less than 3.6 kg or less than 9 months of age.}

References:

1. Rausch-Derra LC, et al. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. AJVR 2015; 76:853-859.
2. Kirkby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016; 2:3-9.
3. Belshaw Z et al. The attitudes of owners and veterinary professionals in the United Kingdom to the risk of adverse events associated with using non-steroidal anti-inflammatory drugs (NSAIDs) to treat dogs with osteoarthritis. Prev Vet Med. 2016; 131: 121-126.
4. Rausch-Derra LC, et al. A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis. JVIM 2016; 30:756-763.

^{For further information contact: 1800 995 709 from anywhere in Australia Monday to Friday or email productsupportau@elancoah.com. Galliprant and Elanco diagonal bar logo are trademarks of Elanco or its affiliates. ©2023 Elanco or its affiliates. PM-AU-23-0224.}